Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.127, Iss.2, 2011-06, pp. : 363-373

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical significance of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy

Oncology Letters, Vol. 9, Iss. 4, 2015-01 ,pp. : 1707-1714

Spandidos Publications

Access to resources Recommend Favorite

Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1 146 patients with early breast cancer

By Arriagada Rodrigo Spielmann Marc Koscielny Serge Le Chevalier Thierry Delozier Thierry Rémé-Saumon Monique Ducourtieux Muriel Tursz Thomas Hill Catherine

Acta Oncologica, Vol. 44, Iss. 5, 2005-07 ,pp. : 458-466

Informa Healthcare

Access to resources Recommend Favorite

Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer

By Petit Thierry

Breast Cancer Research and Treatment, Vol. 124, Iss. 2, 2010-11 ,pp. : 387-391

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant Chemotherapy in Early Breast Cancer: Optimal and Suboptimal Anthracycline-Containing Regimens

By Cocconi G.

Breast Cancer Research and Treatment, Vol. 80, Iss. 3, 2003-08 ,pp. : 313-320

Springer Publishing Company

Access to resources Recommend Favorite

Economic Analyses of Toxicity Secondary to Anthracycline-based Breast Cancer Chemotherapy

By Dranitsaris G. Tran T.M.

European Journal of Cancer, Vol. 31, Iss. 13, 1995-12 ,pp. : 2174-2180

Elsevier

Access to resources Recommend Favorite